Community Health Systems Down Over 15%, On Pace For Largest Percent Decrease Since July 2025 -- Data Talk
Dow Jones2026/10/29 15:25Community Health Systems, Inc. (CYH) is currently at $2.26, down $0.40 or 15.04%
--Would be lowest close since Nov. 1, 2023, when it closed at $2.07
--On pace for largest percent decrease since July 24, 2025, when it fell 25.26%
--Currently down three consecutive days; down 23.13% over this period
--Worst three day stretch since the three days ending July 28, 2025, when it fell 33.51%
--Down 20.98% month-to-date; on pace for worst month since July 2025, when it fell 23.53%
--Down 27.56% year-to-date; on pace for worst year since 2023, when it fell 27.55%
--Down 95.71% from its all-time closing high of $52.71 on June 26, 2015
--Down 45.28% from 52 weeks ago (Oct. 30, 2025), when it closed at $4.13
--Down 45.28% from its 52-week closing high of $4.13 on Oct. 30, 2025
--Would be a new 52-week closing low
--Traded as low as $2.19; lowest intraday level since Nov. 1, 2023, when it hit $2.04
--Down 17.67% at today's intraday low; largest intraday percent decrease since July 24, 2025, when it fell as much as 30.93%
All data as of 11:22:58 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
October 29, 2026 11:25 ET (15:25 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.